Zolantidine is a brain-penetrating histamine H2-receptor antagonist marketed by Smith Kline and French with the research code of SK&F-95282. It is a novel benzthiazole derivative with a 30-fold higher potency for H2-receptors than other peripheral and central receptors.
This page contains content from the copyrighted Wikipedia article "Zolantidine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
